After collecting blood samples from more than 32,000 women, results showed plasma levels of the sTNFR-2, not CRP or IL-6, were linked to an increased risk of CRC. Anti-inflammatory drugs seem to reduce the risk of CRC in women with high, not low, baseline levels of sTNFR-2.
Read the study about the roles of inflammatory markers and NSAIDs in CRC.
Read other coverage about colorectal cancer: